Flupentixol + Melitracen
Flupentixol is used to relieve the symptoms of schizophrenia and other similar mental health problems. Flupentixol belongs to a group of medicines called antipsychotics. Schizophrenia is a mental health condition that causes disordered ideas, beliefs and experiences. Symptoms of schizophrenia include hearing, seeing, or sensing things that are not real, having mistaken beliefs, feeling unusually suspicious, and becoming withdrawn. Flupentixol is used to relieve the symptoms of schizophrenia and other similar mental health problems.
Melitracen is a tricyclic antidepressant (TCA) , for the treatment of depression and anxiety. Melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster oncet of action. Melitracen comes under the category of tricyclic antidepressants which act by decreasing re-uptake of neurotransmitters like norepinephrine and serotonin at the nerve synapse. The cause a high concentration of the neurotransmitters in the next neuron causing an antidepression and anxiety. It has an added advantage of improved tolerability and a slightly faster oncet of action.
Flupentixol in combination with melitracen is indicated to manage symptoms of anxiety, depression, and asthenia in adults. With our commercial data, access important information on dangerous risks, contraindications, and adverse effect. Flupentixol is an antipsychotic agent with anxiolytic and mild sedative actions. It works by blocking the action of dopamine, a chemical messenger in the brain that affects thoughts and mood.
The combination therapy has better efficacy than the monotherapy in improving the symptoms of gastroesophageal reflux in patients with emotional disorders. In addition, this combination treatment is safe, with a low incidence of adverse events.
Drowsiness, dry mouth, constipation, vomiting, dyspepsia, Diarrhea, abdominal pain, nausea, flatulence. Extrapyramidal effects, especially in the initial phase of the treatment. Tachycardia, palpitations, prolonged QT interval, hypotension. Thrombocytopenia, neutropenia, leukopenia, agranulocytosis
